Overexpression of cytoplasmic poly(A)-binding protein 1 as a biomarker for the prognosis and selection of postoperative regimen in breast cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High expression of cytoplasmic poly(A)-binding protein 1 (PABPC1) indicates poor prognosis in breast cancer patients. PABPC1 expression levels can guide treatment selection, particularly for chemotherapy and trastuzumab-based therapies.
Area Of Science
- Oncology
- Molecular Biology
- Biomarker Discovery
Background
- Cytoplasmic poly(A)-binding protein 1 (PABPC1) dysregulation is implicated in various cancers.
- The specific role of PABPC1 in human breast cancer prognosis and treatment response remains largely uncharacterized.
Purpose Of The Study
- To evaluate the impact of PABPC1 expression on the prognosis of breast cancer patients.
- To determine the utility of PABPC1 in guiding the selection of postoperative treatment regimens.
Main Methods
- Analysis of 791 invasive breast cancer cases, with 416 included after propensity score matching (PSM).
- Detection of PABPC1 expression using immunohistochemistry.
- Correlation analysis between PABPC1 expression, clinicopathological factors, treatment regimens, and patient outcomes.
Main Results
- High PABPC1 expression (PABPC1-HE) was observed in 26.8% of cases (212/791).
- PABPC1-HE patients exhibited significantly worse overall survival (OS) and disease-free survival (DFS) post-PSM compared to PABPC1 low expression (PABPC1-LE) patients.
- Postoperative chemotherapy improved OS in PABPC1-HE patients, while endocrine therapy benefited PABPC1-LE patients. PABPC1-HE patients showed improved OS with CT/CRT, especially when combined with trastuzumab.
- Multivariate analysis identified PABPC1-HE as an independent prognostic factor for poor OS and DFS in most breast cancer subtypes.
Conclusions
- PABPC1 serves as a potential biomarker for breast cancer subtyping.
- PABPC1 expression levels can aid in predicting patient prognosis.
- PABPC1 status is valuable for optimizing treatment regimen selection in breast cancer.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
